FDA 510(k)

BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)

K-Nummer: K251713 · 2025-08-08

AntragstellerBecton, Dickinson and Company

Entscheidungsdatum2025-08-08

ProduktcodeLON

BeratungsausschussMI

EntscheidungSubstantially Equivalent

Produktübersicht

BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL) is the device name listed in this FDA 510(k) record. The listed applicant is Becton, Dickinson and Company. It received FDA 510(k) clearance on 2025-08-08 under 510(k) number K251713. The device is classified under product code LON. It was reviewed by the MI advisory panel. FDA Decision: Substantially Equivalent.

Häufig gestellte Fragen

What is the BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)?

BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL) is a medical device that received FDA 510(k) clearance on 2025-08-08. The listed applicant is Becton, Dickinson and Company. The 510(k) number is K251713.

When did BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL) receive FDA 510(k) clearance?

BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL) received FDA 510(k) clearance on 2025-08-08, under 510(k) number K251713.

Who is the listed applicant for BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)?

The FDA 510(k) record lists Becton, Dickinson and Company as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)?

The FDA product code for BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL) is LON.

Zugehörige klinische Studien

Zugehörige Einträge werden automatisch anhand von Namen, Produktcodes oder anderen Metadaten abgeglichen. Eine Übereinstimmung begründet kein verifiziertes klinisches, wissenschaftliches, unternehmerisches oder regulatorisches Verhältnis; prüfen Sie die verlinkten offiziellen Quellen.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITING NCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITING NCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED NCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Weitere Einträge mit Becton, Dickinson and Company als Antragsteller

K262163BD BBL Mueller Hinton II Broth (Cation-Adjusted); BD Difco Mueller Hinton Broth K260128BD Preset™ and BD A-Line™ Arterial Blood Collection Syringes K252378BD® MiniDraw™ Capillary Blood Collection System with BD® MiniDraw™ SST™ Capillary Blood Collection Tube K252506BD Vacutainer® Safety-Lok™ Blood Collection Set; BD Vacutainer® Safety-Lok™ Blood Collection Set with Pre-Attached Holder K260184Onclarity™ Self-Collection Kit K252040BD Vacutainer® Plasma Separator Tubes (PST™), BD Vacutainer® Sodium Heparin Blood Collection Tubes

Alle 102 Geräte anzeigen →

Verwandte Geräte (Code: LON)

K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc.K260281VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)BIOMERIEUX K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc.K250447BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)Becton, Dickinson and Company K234012VITEK COMPACT PRObioMerieux, Inc.K250344BD Phoenix™ Automated Microbiology SystemBecton, Dickinson and Company

Offizielle Quelle

In der FDA-Datenbank anzeigen →

Daten aus der FDA Open API. Für die aktuellsten und verbindlichen Informationen konsultieren Sie bitte stets den offiziellen Datensatz.